MOTS-c in Adults Over 65: What We Know About Safety

What MOTS-c Actually Is and Why It Interests Aging Researchers

MOTS-c is a 16-amino-acid peptide encoded within the 12S rRNA region of mitochondrial DNA. It belongs to a class called mitochondrial-derived peptides (MDPs), small signaling molecules produced by the mitochondrial genome that regulate cellular metabolism and stress responses.

The peptide gained scientific attention after Lee et al. published a 2015 study in Cell Metabolism (N = multiple murine cohorts) demonstrating that exogenous MOTS-c administration improved insulin sensitivity, reduced fat accumulation on a high-fat diet, and activated AMPK-dependent pathways in skeletal muscle [1]. That same research group showed endogenous MOTS-c levels decline with age in both mice and human plasma samples, creating a hypothesis that supplementation could restore metabolic function in older organisms [1].

This age-related decline is what draws geriatric interest. Mitochondrial dysfunction is a recognized hallmark of aging, described in López-Otín et al.'s widely cited 2013 Cell paper on the nine hallmarks of aging [2]. If MOTS-c acts as a retrograde signal from mitochondria to the nucleus (a process called mitonuclear communication), then its decline could contribute to the metabolic deterioration seen after age 60. That is the theory. The clinical evidence has not caught up.

No randomized controlled trial of MOTS-c has been completed in humans of any age as of May 2026. The National Institutes of Health ClinicalTrials.gov registry lists early-phase investigations, but none have published results in geriatric cohorts [3]. Every safety consideration below therefore rests on preclinical data, pharmacologic first principles, and geriatric medicine frameworks rather than direct clinical observation.

Why Geriatric Pharmacology Demands Extra Scrutiny for Peptides

Adults over 65 process drugs differently than younger populations. The American Geriatrics Society (AGS) Beers Criteria, updated in 2023, exists precisely because age-related physiologic changes alter absorption, distribution, metabolism, and elimination of medications in ways that increase adverse event risk [4].

Short peptides like MOTS-c are primarily cleared through renal filtration and enzymatic degradation. Glomerular filtration rate (GFR) declines approximately 1 mL/min/year after age 40, meaning a typical 75-year-old may have a GFR 30-40% lower than a 40-year-old [5]. This reduced clearance can increase systemic exposure to peptide therapeutics, a principle well-established with other renally cleared peptides such as exenatide, where the FDA label specifically warns against use in severe renal impairment [6].

MOTS-c is a small peptide (16 amino acids, approximately 2.2 kDa), and while its exact elimination half-life in humans remains unpublished, peptides of similar size generally undergo rapid renal filtration. Reduced GFR could extend the effective half-life, increase peak plasma concentration, or both. Without pharmacokinetic studies in older adults, the magnitude of this effect is unknown.

Body composition shifts also matter. Older adults have proportionally higher body fat and lower lean mass, which affects the volume of distribution for hydrophilic peptides. Sarcopenia, present in an estimated 10-27% of adults over 60 according to a 2014 meta-analysis published in the Journal of the American Medical Directors Association [7], may also change how MOTS-c interacts with its primary target tissue: skeletal muscle.

Polypharmacy and Drug Interaction Concerns

The average American over 65 takes five or more prescription medications daily. A 2019 analysis published in JAMA Internal Medicine found that 42% of older adults in the U.S. use five or more prescription drugs, with nearly 20% on ten or more [8]. Each additional medication raises the probability of a drug-drug interaction.

MOTS-c activates AMPK (5' adenosine monophosphate-activated protein kinase), the same pathway targeted by metformin [1]. For the large population of older adults already taking metformin for type 2 diabetes, co-administration raises the question of additive or synergistic AMPK activation. Excessive AMPK stimulation could theoretically lower blood glucose beyond intended targets, raising hypoglycemia risk. This is particularly dangerous in older adults, where hypoglycemia increases fall risk and is associated with cardiovascular events. The American Diabetes Association's 2024 Standards of Care recommend less stringent glycemic targets (HbA1c <8.0%) for older adults with multiple comorbidities, specifically to avoid hypoglycemia [9].

Anticoagulant interactions present another concern. Approximately 15% of adults over 65 take warfarin, apixaban, or another blood thinner. Subcutaneous injections in anticoagulated patients carry elevated risk of injection-site hematomas, bruising, and (rarely) abscess formation. While this is a route-of-administration issue rather than a pharmacodynamic interaction, it is a practical safety concern that clinicians must address.

Sulfonylureas, insulin, and SGLT2 inhibitors all carry their own hypoglycemia or hemodynamic risks. Stacking an investigational AMPK activator on top of these regimens without pharmacokinetic data is a clinical gamble. The prudent approach is to assume interaction potential exists until human co-administration studies prove otherwise.

Injection-Site Safety and Practical Administration Risks

Subcutaneous injection is the standard research administration route for MOTS-c, typically at 5 mg per dose three times weekly. For older adults, the injection itself carries considerations that younger patients rarely face.

Skin in adults over 65 is thinner. Dermal atrophy, reduced subcutaneous fat pads, and increased capillary fragility (senile purpura) all increase the likelihood of bruising, bleeding, and poor wound healing at injection sites [10]. These are not trivial cosmetic concerns. Recurrent injection-site reactions can reduce adherence, and in immunocompromised older adults (a common state given age-related immune decline), even minor skin breaks carry infection risk.

Needle gauge and injection technique matter more in geriatric patients. Shorter needles (4-6 mm) with finer gauges (30-31G) reduce pain and bruising risk. Rotation of injection sites is standard practice for any chronic subcutaneous regimen, but compliance with rotation protocols is lower in older adults, particularly those with cognitive impairment or limited dexterity [11].

Self-administration may not be feasible for all geriatric patients. Conditions like arthritis, Parkinson's tremor, or visual impairment can make handling small syringes difficult. A caregiver or home health aide may need to administer injections, adding cost and logistic complexity.

What Preclinical Data Suggest About Aged Organisms

The Lee et al. 2015 Cell Metabolism study remains the foundational reference for MOTS-c's metabolic effects [1]. In diet-induced obese mice, MOTS-c treatment improved glucose tolerance, reduced weight gain, and increased fatty acid oxidation in skeletal muscle. The study demonstrated AMPK activation as a primary mechanism and showed that MOTS-c translocates to the nucleus under metabolic stress to regulate gene expression.

Subsequent preclinical work from the same research group (published 2019 in Cell Metabolism) examined MOTS-c in aged mice and found improved physical capacity and metabolic regulation [12]. Aged mice treated with MOTS-c showed better treadmill performance, lower inflammatory markers, and improved glucose homeostasis compared to vehicle-treated controls.

These results are encouraging but carry the standard caveat: mice are not humans. The translational gap between murine models and geriatric human physiology is wide. Mice do not develop the same pattern of comorbidities, do not take multiple medications, and do not have the same immune senescence profile as a 70-year-old human. Rodent studies also typically use genetically homogeneous populations, the opposite of the genetic diversity seen in human aging cohorts.

A 2020 review in Aging Cell catalogued mitochondrial-derived peptides including MOTS-c and noted that while preclinical signals are "strong across multiple metabolic endpoints," the absence of human pharmacokinetic and safety data represents a critical knowledge gap [13]. The review specifically flagged the need for studies in older populations given the age-related decline in endogenous peptide levels.

Falls, Fractures, and Musculoskeletal Considerations

Falls are the leading cause of injury-related death in Americans over 65, according to CDC data showing over 36,000 fall-related deaths annually [14]. Any intervention in this population must be evaluated through the lens of fall risk, even if the drug itself does not directly cause dizziness or orthostatic hypotension.

MOTS-c's effect on AMPK and glucose metabolism could influence fall risk indirectly. Hypoglycemic episodes cause dizziness, confusion, and loss of coordination. If MOTS-c lowers glucose levels in a patient already on metformin or a sulfonylurea, even mild hypoglycemia could trigger a fall. A single hip fracture in a patient over 75 carries a one-year mortality rate of approximately 20-30%, according to data from a 2010 meta-analysis published in Osteoporosis International [15].

On the potentially beneficial side, MOTS-c's preclinical effects on skeletal muscle function and insulin sensitivity could theoretically improve muscle quality and reduce sarcopenia progression. Better muscle function means better balance. But "theoretically" is doing heavy lifting in that sentence. No human study has measured MOTS-c's effect on grip strength, gait speed, chair-stand time, or any validated geriatric functional assessment.

Until such data exist, clinicians should monitor patients on MOTS-c for any changes in balance, gait, or functional capacity. The Timed Up and Go (TUG) test takes under three minutes and can detect meaningful functional decline between visits.

Renal Monitoring and Dose Adjustment Principles

Without published human pharmacokinetic data, no evidence-based dose adjustment protocol exists for MOTS-c in renal impairment. This is a significant gap. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend that renally cleared drugs be dose-adjusted based on estimated GFR (eGFR), with particular caution at eGFR <30 mL/min/1.73m² [16].

A practical monitoring framework for any clinician prescribing MOTS-c off-label to a geriatric patient should include baseline eGFR (CKD-EPI equation), comprehensive metabolic panel, CBC with differential, fasting glucose and HbA1c, and a repeat panel at 4-6 weeks. Patients with eGFR <45 should be considered higher risk. Patients with eGFR <30 should probably not receive MOTS-c until human renal safety data are available.

Serum creatinine alone is insufficient for monitoring in older adults. Reduced muscle mass can mask true GFR decline by keeping creatinine artificially low. Cystatin C-based eGFR or combined creatinine-cystatin C equations provide more accurate assessment in this population, a point emphasized in the 2021 CKD-EPI update [17].

Deprescribing Context: Where Does MOTS-c Fit in a Medication Review?

Geriatric deprescribing, the systematic process of reducing medication burden, is a growing priority in older adult care. The 2023 AGS Beers Criteria identifies medications that should be avoided or used with caution in adults 75 and older [4]. Adding an investigational peptide to an already complex regimen runs counter to deprescribing principles.

Before starting MOTS-c, a prescriber should conduct a full medication reconciliation. Questions to address: Can any current medications be reduced or eliminated first? Is the patient's glycemic target appropriate for their age and comorbidity burden? Are there existing supplements (NAD+ precursors, CoQ10, other mitochondrial-targeting compounds) that could interact with or duplicate MOTS-c's effects?

The STOPP/START criteria, developed for European geriatric populations and published in Age and Ageing [18], provide a complementary framework. STOPP (Screening Tool of Older Persons' Prescriptions) identifies potentially inappropriate medications, while START (Screening Tool to Alert to Right Treatment) identifies beneficial medications that are being omitted. MOTS-c, as an investigational compound, would not appear on either list. Its absence from validated deprescribing frameworks is itself a safety signal: the evidence base does not support routine use.

Immunosenescence and Peptide Metabolism in Aging Immune Systems

Aging reshapes the immune system in ways that could affect both the safety and efficacy of exogenous peptides. Immunosenescence, the gradual decline in immune function, is characterized by reduced naive T-cell production, increased inflammatory cytokine baseline (sometimes called "inflammaging"), and impaired wound healing [19].

MOTS-c has demonstrated anti-inflammatory properties in preclinical models. Reynolds et al. showed that MOTS-c reduced inflammatory cytokine expression (TNF-alpha, IL-6) in stressed cell cultures [12]. In an older adult with chronic low-grade inflammation, this could be beneficial. It could also suppress immune responses that are already compromised.

The immune system of a 75-year-old responds differently to foreign peptides than a 30-year-old's. Potential for antibody formation against exogenous MOTS-c (anti-drug antibodies) has not been studied. Biologics and peptide drugs commonly trigger anti-drug antibody responses that can reduce efficacy or cause hypersensitivity reactions. The incidence tends to be higher in older adults with dysregulated immune systems. This remains entirely unstudied for MOTS-c.

A Realistic Risk-Benefit Assessment for the 65+ Population

The honest assessment is this: MOTS-c has strong preclinical signals for metabolic improvement, and the age-related decline in endogenous levels provides a biological rationale for supplementation in older adults. The preclinical data from Lee et al. [1] and follow-up studies [12] are consistent and mechanistically coherent. AMPK activation, improved glucose handling, reduced inflammation, and better exercise capacity in aged mice are exactly the outcomes geriatric medicine would want.

But preclinical promise is not clinical evidence. The history of medicine is filled with compounds that worked beautifully in mice and failed or harmed humans. Without Phase I safety data in any human population, and without Phase II efficacy data in older adults, MOTS-c remains an experimental compound with an unknown risk profile in the population most likely to be vulnerable to its potential adverse effects.

For clinicians considering off-label MOTS-c in geriatric patients, the minimum responsible approach includes informed consent that explicitly states the absence of human safety data, baseline and periodic monitoring of renal function, glucose, and hematologic parameters, coordination with all prescribers to assess interaction risk, starting at the lowest available dose with slow titration, and clear stopping criteria (defined glucose thresholds, renal function decline, injection-site complications).

Patients and caregivers should understand that "available from a compounding pharmacy" does not mean "tested and approved for use in older adults." Compounded peptides also carry purity and sterility variability that FDA-approved drugs do not, a concern the FDA addressed directly in a 2023 safety communication about compounded peptide products [20].

Baseline eGFR should be above 45 mL/min/1.73m² before initiating MOTS-c in any patient over 65, with repeat measurement at 4 weeks and quarterly thereafter.